Entropin Inc has entered into a research agreement with a specialty pharmaceutical company that owns U.S. and international patent and other proprietary rights to technologies that enhance or facilitate the absorption of drugs across biological membranes. Pursuant to the agreement, Entropin and its partner have entered into a research-based collaboration to evaluate the compatibility and feasibility of developing topical pain product(s) containing Entropin's proprietary compound, ENT-103 and the research partner's proprietary excipient, in a proprietary topical delivery formulation.

"We are excited about our agreement and pleased that a respected pharmaceutical company with a demonstrated track record has reviewed the preclinical data collected on ENT-103 and has the desire to further explore ENT-103's potential as a pain relief product in combination with their proprietary topical delivery technology. If the results of our research are positive, we look forward to collaborating with such a respected specialty pharmaceutical company on the development of new products," commented Thomas G. Tachovsky, President and CEO of Entropin. "We believe the results of this research could help demonstrate a second way to deliver ENT-103 to solve significant medical problems as the Company continues its work on the development of ENT-103 as an injectible," added Dr. Tachovsky. "Although the terms of our mutual confidentiality agreement preclude us from naming our partner at this time, we look forward to disclosing their identity upon completion of our initial studies," concluded Dr. Tachovsky.

Under the agreement, our research partner will combine its proprietary excipient which promotes enhanced absorption of drugs across dermal, mucosal and ocular membranes with ENT-103 to analyze their compatibility. Our partner's formulations will then be tested by Entropin's collaborators at Harvard Medical School and the University of Arizona. The purpose of this research is to determine the feasibility of developing new products for commercialization.

In January 2003 Entropin announced that it was refocusing its research on the development of ENT-103, a simplified version of its potent analgesic/anesthetic, ENT-102 and the Company filed a new composition-of-matter patent for ENT-103. Since that announcement, the Company has performed significant preclinical testing of ENT-103. The data from these preclinical studies has further supported the unique characteristics of this compound and has provided the impetus for this research collaboration.